Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 2/20 | 0.39 |
| ▸ | NOS1 | P29475 | 2/20 | 0.39 |
| ▸ | NOS2 | P35228 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 11/20 | 0.35 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25320073 | 1.00 | NOS3 (0.39) | NOS3NOS1NOS2MEN1KMT2A | |
| SCHEMBL30551554 | 1.00 | NOS3 (0.39) | NOS3NOS1NOS2MEN1KMT2A | |
| Trifluoroacetic Acid SCHEMBL25322362 | 0.87 | EGFR (0.38) | MEN1KMT2AALDH1A1MAPTMAPK1 | |
| SCHEMBL24366285 | 0.86 | KDM1A (0.37) | NOS3NOS1NOS2EGFRNISCH | |
| SCHEMBL29324131 | 0.86 | NOS3 (0.36) | NOS3NOS1NOS2EGFRNISCH | |
| SCHEMBL29081543 | 0.86 | NOS3 (0.36) | NOS3NOS1NOS2MEN1KMT2A | |
| SCHEMBL24363895 | 0.86 | HSD17B1 (0.38) | NOS3NOS1NOS2MEN1KMT2A | |
| SCHEMBL30470148 | 0.86 | HSD17B1 (0.38) | NOS3NOS1NOS2MEN1KMT2A | |
| SCHEMBL31145086 | 0.86 | KDM1A (0.37) | NOS3NOS1NOS2EGFRNISCH | |
| SCHEMBL30470920 | 0.86 | NOS3 (0.36) | NOS3NOS1NOS2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250163048-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| EP-4469455-A1 | COMPOUNDS AND METHODS OF USE | Tango Therapeutics, Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| WO-2023146990-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250163048-A1 | COMPOUNDS AND METHODS OF USE | RB1, CYP1B1, REN | NOS3 3132/4885NOS1 2495/4885NOS2 2374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.